Clinical association between the metabolite of healthy gut microbiota, 3-indolepropionic acid and chronic kidney disease

Chiao Yin Sun, Cheng Jui Lin, Heng Chih Pan, Chin Chan Lee, Shang Chieh Lu, Yu Ting Hsieh, Shih Yi Huang, Hui Yu Huang

Research output: Contribution to journalArticle

Abstract

Background & aims: Emerging evidence indicates that gut microbiota serves an important role in the development and progression of chronic kidney disease (CKD). Changes to the gut microbial flora can cause the generation of uremic toxins, which contribute to chronic kidney injury. The aim of the current study was to explore the clinical association between metabolites and CKD. Methods: Between August 2013 and January 2015, a two-phase case–control study was conducted to analyze the clinical association between metabolites and CKD in a community health program. The first phase of the study was a prospective case–control survey designed for comparing the differences in the metabolome profile of patients with (n = 10) and without (n = 10) estimated glomerular filtration rate (eGFR) rapid decline (a yearly decline >20%). The second phase of the study was a cross-sectional case–control study, which checked and compared the metabolites, indoxyl sulfate and p-cresol sulfate levels between healthy subjects (n = 144) and CKD patients (n = 140). Results: In the first phase of the study, it was revealed that IPA levels of patients with rapid renal function decline were significantly reduced compared with the control patients (n = 10 for each group). The second phase furthered checked and compared the IPA, indoxyl sulfate and p-cresol sulfate levels between healthy subjects (n = 144) and CKD patients (n = 140). The results showed that the average level of indoxyl sulfate (2738.2 vs. 541.0 ng/ml, P < 0.01) and p-cresol sulfate (1442.8 vs. 1394.6 ng/ml, P < 0.01) were significantly higher in the CKD patients, while the average level of IPA was significantly higher (49.8 vs. 34.7 ng/ml, P < 0.01) in the control patients. Conclusions: Our results suggest that IPA might be an important biomarker and renal protector against the development of CKD.

Original languageEnglish
JournalClinical Nutrition
DOIs
Publication statusPublished - 2019

Fingerprint

Chronic Renal Insufficiency
Indican
Kidney
Healthy Volunteers
Metabolome
Gastrointestinal Microbiome
3-(indol-3-yl)propionic acid
Glomerular Filtration Rate
Cross-Sectional Studies
Biomarkers
Health
Wounds and Injuries
4-cresol sulfate

Keywords

  • 3-Indolepropionic acid
  • Chronic kidney disease
  • Gut microbiota

ASJC Scopus subject areas

  • Nutrition and Dietetics
  • Critical Care and Intensive Care Medicine

Cite this

Clinical association between the metabolite of healthy gut microbiota, 3-indolepropionic acid and chronic kidney disease. / Sun, Chiao Yin; Lin, Cheng Jui; Pan, Heng Chih; Lee, Chin Chan; Lu, Shang Chieh; Hsieh, Yu Ting; Huang, Shih Yi; Huang, Hui Yu.

In: Clinical Nutrition, 2019.

Research output: Contribution to journalArticle

Sun, Chiao Yin ; Lin, Cheng Jui ; Pan, Heng Chih ; Lee, Chin Chan ; Lu, Shang Chieh ; Hsieh, Yu Ting ; Huang, Shih Yi ; Huang, Hui Yu. / Clinical association between the metabolite of healthy gut microbiota, 3-indolepropionic acid and chronic kidney disease. In: Clinical Nutrition. 2019.
@article{4de8e9f8be6845c898e9339ba1374181,
title = "Clinical association between the metabolite of healthy gut microbiota, 3-indolepropionic acid and chronic kidney disease",
abstract = "Background & aims: Emerging evidence indicates that gut microbiota serves an important role in the development and progression of chronic kidney disease (CKD). Changes to the gut microbial flora can cause the generation of uremic toxins, which contribute to chronic kidney injury. The aim of the current study was to explore the clinical association between metabolites and CKD. Methods: Between August 2013 and January 2015, a two-phase case–control study was conducted to analyze the clinical association between metabolites and CKD in a community health program. The first phase of the study was a prospective case–control survey designed for comparing the differences in the metabolome profile of patients with (n = 10) and without (n = 10) estimated glomerular filtration rate (eGFR) rapid decline (a yearly decline >20{\%}). The second phase of the study was a cross-sectional case–control study, which checked and compared the metabolites, indoxyl sulfate and p-cresol sulfate levels between healthy subjects (n = 144) and CKD patients (n = 140). Results: In the first phase of the study, it was revealed that IPA levels of patients with rapid renal function decline were significantly reduced compared with the control patients (n = 10 for each group). The second phase furthered checked and compared the IPA, indoxyl sulfate and p-cresol sulfate levels between healthy subjects (n = 144) and CKD patients (n = 140). The results showed that the average level of indoxyl sulfate (2738.2 vs. 541.0 ng/ml, P < 0.01) and p-cresol sulfate (1442.8 vs. 1394.6 ng/ml, P < 0.01) were significantly higher in the CKD patients, while the average level of IPA was significantly higher (49.8 vs. 34.7 ng/ml, P < 0.01) in the control patients. Conclusions: Our results suggest that IPA might be an important biomarker and renal protector against the development of CKD.",
keywords = "3-Indolepropionic acid, Chronic kidney disease, Gut microbiota",
author = "Sun, {Chiao Yin} and Lin, {Cheng Jui} and Pan, {Heng Chih} and Lee, {Chin Chan} and Lu, {Shang Chieh} and Hsieh, {Yu Ting} and Huang, {Shih Yi} and Huang, {Hui Yu}",
year = "2019",
doi = "10.1016/j.clnu.2018.11.029",
language = "English",
journal = "Clinical Nutrition",
issn = "0261-5614",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Clinical association between the metabolite of healthy gut microbiota, 3-indolepropionic acid and chronic kidney disease

AU - Sun, Chiao Yin

AU - Lin, Cheng Jui

AU - Pan, Heng Chih

AU - Lee, Chin Chan

AU - Lu, Shang Chieh

AU - Hsieh, Yu Ting

AU - Huang, Shih Yi

AU - Huang, Hui Yu

PY - 2019

Y1 - 2019

N2 - Background & aims: Emerging evidence indicates that gut microbiota serves an important role in the development and progression of chronic kidney disease (CKD). Changes to the gut microbial flora can cause the generation of uremic toxins, which contribute to chronic kidney injury. The aim of the current study was to explore the clinical association between metabolites and CKD. Methods: Between August 2013 and January 2015, a two-phase case–control study was conducted to analyze the clinical association between metabolites and CKD in a community health program. The first phase of the study was a prospective case–control survey designed for comparing the differences in the metabolome profile of patients with (n = 10) and without (n = 10) estimated glomerular filtration rate (eGFR) rapid decline (a yearly decline >20%). The second phase of the study was a cross-sectional case–control study, which checked and compared the metabolites, indoxyl sulfate and p-cresol sulfate levels between healthy subjects (n = 144) and CKD patients (n = 140). Results: In the first phase of the study, it was revealed that IPA levels of patients with rapid renal function decline were significantly reduced compared with the control patients (n = 10 for each group). The second phase furthered checked and compared the IPA, indoxyl sulfate and p-cresol sulfate levels between healthy subjects (n = 144) and CKD patients (n = 140). The results showed that the average level of indoxyl sulfate (2738.2 vs. 541.0 ng/ml, P < 0.01) and p-cresol sulfate (1442.8 vs. 1394.6 ng/ml, P < 0.01) were significantly higher in the CKD patients, while the average level of IPA was significantly higher (49.8 vs. 34.7 ng/ml, P < 0.01) in the control patients. Conclusions: Our results suggest that IPA might be an important biomarker and renal protector against the development of CKD.

AB - Background & aims: Emerging evidence indicates that gut microbiota serves an important role in the development and progression of chronic kidney disease (CKD). Changes to the gut microbial flora can cause the generation of uremic toxins, which contribute to chronic kidney injury. The aim of the current study was to explore the clinical association between metabolites and CKD. Methods: Between August 2013 and January 2015, a two-phase case–control study was conducted to analyze the clinical association between metabolites and CKD in a community health program. The first phase of the study was a prospective case–control survey designed for comparing the differences in the metabolome profile of patients with (n = 10) and without (n = 10) estimated glomerular filtration rate (eGFR) rapid decline (a yearly decline >20%). The second phase of the study was a cross-sectional case–control study, which checked and compared the metabolites, indoxyl sulfate and p-cresol sulfate levels between healthy subjects (n = 144) and CKD patients (n = 140). Results: In the first phase of the study, it was revealed that IPA levels of patients with rapid renal function decline were significantly reduced compared with the control patients (n = 10 for each group). The second phase furthered checked and compared the IPA, indoxyl sulfate and p-cresol sulfate levels between healthy subjects (n = 144) and CKD patients (n = 140). The results showed that the average level of indoxyl sulfate (2738.2 vs. 541.0 ng/ml, P < 0.01) and p-cresol sulfate (1442.8 vs. 1394.6 ng/ml, P < 0.01) were significantly higher in the CKD patients, while the average level of IPA was significantly higher (49.8 vs. 34.7 ng/ml, P < 0.01) in the control patients. Conclusions: Our results suggest that IPA might be an important biomarker and renal protector against the development of CKD.

KW - 3-Indolepropionic acid

KW - Chronic kidney disease

KW - Gut microbiota

UR - http://www.scopus.com/inward/record.url?scp=85059433170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059433170&partnerID=8YFLogxK

U2 - 10.1016/j.clnu.2018.11.029

DO - 10.1016/j.clnu.2018.11.029

M3 - Article

JO - Clinical Nutrition

JF - Clinical Nutrition

SN - 0261-5614

ER -